Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;34(5):797-801.
doi: 10.1038/s41433-019-0607-8. Epub 2019 Sep 30.

Abicipar pegol: the non-monoclonal antibody anti-VEGF

Ashish Sharma  1 , Nilesh Kumar  2 , Baruch D Kuppermann  3 , Francesco Bandello  4
Affiliations

Abicipar pegol: the non-monoclonal antibody anti-VEGF

Ashish Sharma et al. Eye (Lond). 2020 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Ashish Sharma: Consultant—Novartis India, Allergan Global, Intas India, Bayer India. Nilesh Kumar: None. BD Kuppermann: Clinical research—Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics; Consultant—Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma. Francesco Bandello: Consultant—Allergan, Bayer, Boehringer- Ingelheim, Fidia Sooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss.

Figures

Fig. 1
Fig. 1
Molecular structure of DARPin
See this image and copyright information in PMC

References

    1. Stahl A, Stumpp MT, Schlegel A, Ekawardhani S, Lehrling C, Martin G, et al. Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. Angiogenesis. 2013;16:101–11. doi: 10.1007/s10456-012-9302-0. - DOI - PMC - PubMed
    1. Smithwick E, Stewart MW. Designed ankyrin repeat proteins: a look at their evolving use in medicine with a focus on the treatment of chorioretinal vascular disorders. AIAAMC. 2017;16:1–1. doi: 10.2174/1871523016666170502115816. - DOI - PubMed
    1. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148:43–58.e1. doi: 10.1016/j.ajo.2009.01.024. - DOI - PubMed
    1. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663–71. doi: 10.1016/j.ophtha.2010.12.019. - DOI - PubMed
    1. Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119:1175–83. doi: 10.1016/j.ophtha.2011.12.016. - DOI - PubMed